<DOC>
	<DOCNO>NCT02566564</DOCNO>
	<brief_summary>Phase I/IIa study determine safety clinical effect intra-articular injection MTX-071 ( Lopain ) patient chronic osteoarthritic knee-joint pain .</brief_summary>
	<brief_title>Intra-articular Lopain ( MTX-071 ) Phase I/IIa Study Chronic Osteoarthritic Knee Joint Pain</brief_title>
	<detailed_description>Open label , single-dose , dose-escalating phase I/IIa study determine safety clinical effect intra-articular injection MTX-071 ( Lopain ) patient chronic osteoarthritic knee-joint pain .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Arthralgia</mesh_term>
	<criteria>Written inform consent Written inform consent Men woman age 40 70 year At least 40 mm motion least 10 mm rest 100 mmVAS ( Visual Analog Scale ) average arthritic joint pain knee study last 2 day , without pain medication . Previously document radiography show Kellgren Lawrence Grade 2 4 severity . Female patient childbearing potential female partner childbearing potential male patient must agree use reliable contraceptive method least one month injection MTX071 . Subject highly likely comply protocol complete study . Knee surgery within 6 month study start plan time next 6 month . Any injection knee study within precede 7 day trauma knee yet heal . History clinically significant cardiac , renal , and/or relevant disease malignancy . History severe allergic anaphylactic reaction . Pregnancy . Major bleed disorder . Clinically significant deviation normal laboratory value . Clinically significant abnormal ECG History clinically relevant drug/chemical/ substance/alcohol abuse within past 2 year prior screen . Symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within past 2 week prior study medication administration . Patients positive human immunodeficiency virus ( HIV ) antibody , hepatitis C antibody , hepatitis B virus surface antigen ( HBsAg ) , tuberculosis . Patients corticosteroid injection knee study within 3 month prior baseline plan get corticosteroid injection within 4 week follow injection MTX071 . Vaccination within 60 day prior study medication administration . Systemic immunosuppressant agent within 6 month prior study medication administration Experimental agent within 30 day ten halflives , whichever longer , prior study medication administration . Any condition , opinion investigator , preclude subject 's participation trial . Patients dependent sponsor investigator .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>